View Older Stories View More Recent Stories

Nov 26, 2025 04:05PM Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Nov 10, 2025 04:05PM Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 7, 2025 06:10PM Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
Nov 5, 2025 04:05PM Mineralys Therapeutics to Participate in Upcoming Investor Conferences
Nov 3, 2025 08:00AM Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025
Oct 21, 2025 08:00AM Mineralys to present Phase 2 CKD trial data at ASN Kidney Week 2025
Oct 21, 2025 08:00AM Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025
Sep 30, 2025 08:01AM Mineralys completes enrollment in sleep apnea drug trial
Sep 30, 2025 08:00AM Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension
Sep 5, 2025 09:00AM Mineralys shows lorundrostat effective across diverse hypertension groups
Sep 5, 2025 09:00AM Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need  
Sep 2, 2025 04:01PM Mineralys Therapeutics launches $175 million public stock offering
Sep 2, 2025 04:01PM Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
Aug 12, 2025 04:05PM Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 4, 2025 04:05PM Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025
Jun 30, 2025 11:19AM Mineralys Therapeutics (MLYS) announces positive results from Phase 3 Launch-HTN trial
Jun 30, 2025 11:17AM Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
Jun 17, 2025 07:00AM Mineralys Therapeutics (MLYS) Announces Positive Topline Results from Phase 2 Explore-CKD Trial
Jun 17, 2025 07:00AM Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
May 24, 2025 04:30AM Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension
May 20, 2025 08:01AM Mineralys Therapeutics (MLYS) Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
May 20, 2025 08:00AM Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
May 12, 2025 04:05PM Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 7, 2025 08:00AM Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
May 5, 2025 04:05PM Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025
Apr 23, 2025 05:25PM Mineralys Therapeutics (MLYS) announces publication of phase 2 Advance-HTN results
Apr 23, 2025 05:23PM Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)
Mar 29, 2025 02:30PM Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual
Mar 25, 2025 08:00AM Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
Mar 17, 2025 08:00AM Mineralys Therapeutics (MLYS) Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat
Mar 17, 2025 08:00AM Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College
Mar 10, 2025 07:01AM Mineralys Therapeutics (MLYS) Announces Positive Topline Results from Launch-HTN and Advance-HTN Trials of Lorundrostat
Mar 10, 2025 07:00AM Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
Mar 7, 2025 04:01PM Mineralys Therapeutics (MLYS) to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
Mar 7, 2025 04:01PM Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
Feb 12, 2025 07:00AM Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Feb 5, 2025 04:05PM Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025
Feb 4, 2025 08:06AM Mineralys Therapeutics (MLYS) Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria
Feb 4, 2025 08:00AM Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria
Jan 8, 2025 08:06AM Mineralys Therapeutics (MLYS) Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
Jan 8, 2025 08:00AM Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
Nov 11, 2024 04:05PM Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Nov 5, 2024 04:05PM Mineralys Therapeutics to Participate in Upcoming Investor Conferences
Nov 4, 2024 04:05PM Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024
Oct 30, 2024 08:00AM Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
Oct 22, 2024 08:00AM Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024
Sep 25, 2024 08:00AM Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension
Aug 28, 2024 08:00AM Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference
Aug 13, 2024 04:05PM Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Aug 5, 2024 04:05PM Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
View More Recent Stories View Older Stories